Personalis Total Liabilities 2018-2024 | PSNL

Personalis total liabilities from 2018 to 2024. Total liabilities can be defined as the total value of all possible claims against the corporation.
Personalis Annual Total Liabilities
(Millions of US $)
2023 $96
2022 $75
2021 $86
2020 $50
2019 $51
2018 $148
2017 $0
Personalis Quarterly Total Liabilities
(Millions of US $)
2024-09-30 $73
2024-06-30 $73
2024-03-31 $75
2023-12-31 $96
2023-09-30 $75
2023-06-30 $73
2023-03-31 $79
2022-12-31 $75
2022-09-30 $75
2022-06-30 $93
2022-03-31 $94
2021-12-31 $86
2021-09-30 $81
2021-06-30 $45
2021-03-31 $47
2020-12-31 $50
2020-09-30 $45
2020-06-30 $52
2020-03-31 $53
2019-12-31 $51
2019-09-30 $48
2019-06-30 $75
2019-03-31 $0
2018-12-31
2018-09-30 $0
2018-06-30 $0
2017-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.245B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Supernus Pharmaceuticals (SUPN) United States $2.000B 27.23
Taysha Gene Therapies (TSHA) United States $0.506B 35.29
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00